Taylor WD. Clinical practice. Depression in the elderly. N Engl J Med. 2014;371:1228–36.
Blazer DG. Depression in late life: review and commentary. J Gerontol A Biol Sci Med Sci. 2003;58:249–65.
Lyness JM, Caine ED, King DA, Cox C, Yoediono Z. Psychiatric disorders in older primary care patients. J Gen Intern Med. 1999;14:249–54.
Steffens DC, Hays JC, Krishnan KR. Disability in geriatric depression. Am J Geriatr Psychiatry. 1999;7:34–40.
Jiang W, Alexander J, Christopher E, Kuchibhatla M, Gaulden LH, Cuffe MS, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med. 2001;161:1849–56.
Conwell Y, Thompson C. Suicidal behavior in elders. Psychiatr Clin North Am. 2008;31:333–56.
Penninx BW, Geerlings SW, Deeg DJ, van Eijk JT, van Tilburg W, Beekman AT. Minor and major depression and the risk of death in older persons. Arch Gen Psychiatry. 1999;56:889–95.
Manning KJ, Steffens DC. State of the science of neural systems in late-life depression: impact on clinical presentation and treatment outcome. J Am Geriatr Soc. 2018;66:S17–S23.
Sexton CE, McDermott L, Kalu UG, Herrmann LL, Bradley KM, Allan CL, et al. Exploring the pattern and neural correlates of neuropsychological impairment in late-life depression. Psychol Med. 2012;42:1195–202.
Boone KB, Lesser IM, Miller BL, Wohl M, Berman N, Lee ABP, et al. Cognitive functioning in older depressed outpatients: relationship of presence and severity of depression to neuropsychological test scores. Neuropsychology. 1995;9:390–8.
Sheline YI, Barch DM, Garcia K, Gersing K, Piper C, Welsh-Bohmer KA, et al. Cognitive function in late life depression: relationships to depression severity, cerebrovascular risk factors and processing speed. Biol Psychiatry. 2006;60:58–65.
Butters MA, Whyte EM, Nebes RD, Begley AE, Dew MA, Mulsant BH, et al. The nature and determinants of neuropsychological functioning in late-life depression. Arch Gen Psychiatry. 2004;61:587–95.
Nebes RD, Butters MA, Mulsant BH, Pollock BG, Zmuda MD, Houck PR, et al. Decreased working memory and processing speed mediate cognitive impairment in geriatric depression. Psychol Med. 2000;30:679–91.
Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF 3rd. Late-life depression and risk of vascular dementia and Alzheimer’s disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry. 2013;202:329–35.
Andreescu C, Ajilore O, Aizenstein HJ, Albert K, Butters MA, Landman BA, et al. Disruption of neural homeostasis as a model of relapse and recurrence in late-life depression. Am J Geriatr Psychiatry. 2019;27:1316–30.
Deng Y, McQuoid DR, Potter GG, Steffens DC, Albert K, Riddle M, et al. Predictors of recurrence in remitted late-life depression. Depress Anxiety. 2018;35:658–67.
Reynolds CF, Frank E, Perel JM, Imber SD, Cornes C, Miller MD, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. J Am Med Assoc. 1999;281:39–45.
Reynolds CF 3rd, Dew MA, Pollock BG, Mulsant BH, Frank E, Miller MD, et al. Maintenance treatment of major depression in old age. N Engl J Med. 2006;354:1130–8.
Alexopoulos GS, Meyers BS, Young RC, Kalayam B, Kakuma T, Gabrielle M, et al. Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry. 2000;57:285–90.
Sachs-Ericsson N, Corsentino E, Moxley J, Hames JL, Rushing NC, Sawyer K, et al. A longitudinal study of differences in late- and early-onset geriatric depression: depressive symptoms and psychosocial, cognitive, and neurological functioning. Aging Ment Health. 2013;17:1–11.
Klein DN, Schatzberg AF, McCullough JP, Dowling F, Goodman D, Howland RH, et al. Age of onset in chronic major depression: relation to demographic and clinical variables, family history, and treatment response. J Affect Disord. 1999;55:149–57.
Markett S, Montag C, Reuter M. Network neuroscience and personality. Personal Neurosci. 2018;1:e14.
Newhouse P, Albert K. Estrogen, stress, and depression: a neurocognitive model. JAMA Psychiatry 2015;72:727–9.
Park C, Rosenblat JD, Brietzke E, Pan Z, Lee Y, Cao B, et al. Stress, epigenetics and depression: a systematic review. Neurosci Biobehav Rev. 2019;102:139–52.
Janssen J, Beekman AT, Comijs HC, Deeg DJ, Heeren TJ. Late-life depression: the differences between early- and late-onset illness in a community-based sample. Int J Geriatr Psychiatry. 2006;21:86–93.
Baldwin RC, Tomenson B. Depression in later life: a comparison of symptoms and risk factors in early and late onset cases. Br J Psychiatry. 1995;167:649–52.
Lavretsky H, Lesser IM, Wohl M, Miller BL. Relationship of age, age at onset, and sex to depression in older adults. Am J Geriatr Psychiatry. 1998;6:248–56.
Dillon C, Allegri RF, Serrano CM, Iturry M, Salgado P, Glaser FB, et al. Late- versus early-onset geriatric depression in a memory research center. Neuropsychiatr Dis Treat. 2009;5:517–26.
Rapp MA, Dahlman K, Sano M, Grossman HT, Haroutunian V, Gorman JM. Neuropsychological differences between late-onset and recurrent geriatric major depression. Am J Psychiatry. 2005;162:691–8.
Salloway S, Malloy P, Kohn R, Gillard E, Duffy J, Rogg J, et al. MRI and neuropsychological differences in early- and late-life-onset geriatric depression. Neurology. 1996;46:1567–74.
Riddle M, Potter GG, McQuoid DR, Steffens DC, Beyer JL, Taylor WD. Longitudinal cognitive outcomes of clinical phenotypes of late-life depression. Am J Geriatr Psychiatry. 2017;25:1123–34.
Ly M, Karim HT, Becker JT, Lopez OL, Anderson SJ, Aizenstein HJ, et al. Late-life depression and increased risk of dementia: a longitudinal cohort study. Transl Psychiatry. 2021;11:147.
Menon V. Large-scale brain networks and psychopathology: a unifying triple network model. Trends Cogn Sci. 2011;15:483–506.
Gunning FM, Oberlin LE, Schier M, Victoria LW. Brain-based mechanisms of late-life depression: implications for novel interventions. Semin Cell Dev Biol. 2021;116:169–79.
Keren H, O’Callaghan G, Vidal-Ribas P, Buzzell GA, Brotman MA, Leibenluft E, et al. Reward processing in depression: a conceptual and meta-analytic review across fMRI and EEG studies. Am J Psychiatry. 2018;175:1111–20.
Zhang WN, Chang SH, Guo LY, Zhang KL, Wang J. The neural correlates of reward-related processing in major depressive disorder: a meta-analysis of functional magnetic resonance imaging studies. J Affect Disord. 2013;151:531–9.
Taylor WD, Zald DH, Felger JC, Christman S, Claassen DO, Horga G, et al. Influences of dopaminergic system dysfunction on late-life depression. Mol Psychiatry. 2022;27:180–91.
Saberi A, Mohammadi E, Zarei M, Eickhoff SB, Tahmasian M. Structural and functional neuroimaging of late-life depression: a coordinate-based meta-analysis. Brain Imaging Behav. 2022;16:518–31.
Manning K, Wang L, Steffens D. Recent advances in the use of imaging in psychiatry: functional magnetic resonance imaging of large-scale brain networks in late-life depression. F1000Res. 2019;8:F1000.
Buckner RL, Andrews-Hanna JR, Schacter DL. The brain’s default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008;1124:1–38.
Zhou HX, Chen X, Shen YQ, Li L, Chen NX, Zhu ZC, et al. Rumination and the default mode network: Meta-analysis of brain imaging studies and implications for depression. Neuroimage. 2020;206:116287.
Kaiser RH, Andrews-Hanna JR, Wager TD, Pizzagalli DA. Large-scale network dysfunction in major depressive disorder: a meta-analysis of resting-state functional connectivity. JAMA Psychiatry. 2015;72:603–11.
Scalabrini A, Vai B, Poletti S, Damiani S, Mucci C, Colombo C, et al. All roads lead to the default-mode network-global source of DMN abnormalities in major depressive disorder. Neuropsychopharmacology. 2020;45:2058–69.
Javaheripour N, Li M, Chand T, Krug A, Kircher T, Dannlowski U, et al. Altered resting-state functional connectome in major depressive disorder: a mega-analysis from the PsyMRI consortium. Transl Psychiatry. 2021;11:511.
Tozzi L, Zhang X, Chesnut M, Holt-Gosselin B, Ramirez CA, Williams LM. Reduced functional connectivity of default mode network subsystems in depression: meta-analytic evidence and relationship with trait rumination. Neuroimage Clin. 2021;30:102570.
Wu M, Andreescu C, Butters MA, Tamburo R, Reynolds CF 3rd, Aizenstein H. Default-mode network connectivity and white matter burden in late-life depression. Psychiatr Res. 2011;194:39–46.
Gandelman JA, Albert K, Boyd BD, Park JW, Riddle M, Woodward ND, et al. Intrinsic functional network connectivity is associated with clinical symptoms and cognition in late-life depression. Biol Psychiatry Cogn Neurosci Neuroimaging. 2019;4:160–70.
Niendam TA, Laird AR, Ray KL, Dean YM, Glahn DC, Carter CS. Meta-analytic evidence for a superordinate cognitive control network subserving diverse executive functions. Cogn Affect Behav Neurosci. 2012;12:241–68.
Gerlach AR, Karim HT, Pecina M, Ajilore O, Taylor WD, Butters MA, et al. MRI predictors of pharmacotherapy response in major depressive disorder. Neuroimage Clin. 2022;36:103157.
Dotson VM, McClintock SM, Verhaeghen P, Kim JU, Draheim AA, Syzmkowicz SM, et al. Depression and cognitive control across the lifespan: a systematic review and meta-analysis. Neuropsychol Rev. 2020;30:461–76.
Lockwood KA, Alexopoulos GS, van Gorp WG. Executive dysfunction in geriatric depression. Am J Psychiatry. 2002;159:1119–26.
Kim J, Kim Y-K. Crosstalk between depression and dementia with resting-state fMRI studies and its relationship with cognitive functioning. Biomedicines. 2021;9:82.
Menon V, Uddin LQ. Saliency, switching, attention and control: a network model of insula function. Brain Struct Funct. 2010;214:655–67.
Berman MG, Nee DE, Casement M, Kim HS, Deldin P, Kross E, et al. Neural and behavioral effects of interference resolution in depression and rumination. Cogn Affect Behav Neurosci. 2011;11:85–96.
Hamilton JP, Furman DJ, Chang C, Thomason ME, Dennis E, Gotlib IH. Default-mode and task-positive network activity in major depressive disorder: implications for adaptive and maladaptive rumination. Biol Psychiatry. 2011;70:327–33.
Goldstein-Piekarski AN, Ball TM, Samara Z, Staveland BR, Keller AS, Fleming SL, et al. Mapping neural circuit biotypes to symptoms and behavioral dimensions of depression and anxiety. Biol Psychiatry. 2022;91:561–71.
Yun JY, Kim YK. Graph theory approach for the structural-functional brain connectome of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2021;111:110401.
Rizvi SJ, Pizzagalli DA, Sproule BA, Kennedy SH. Assessing anhedonia in depression: potentials and pitfalls. Neurosci Biobehav Rev. 2016;65:21–35.
Andrews-Hanna JR, Snyder AZ, Vincent JL, Lustig C, Head D, Raichle ME, et al. Disruption of large-scale brain systems in advanced aging. Neuron. 2007;56:924–35.
Jockwitz C, Caspers S. Resting-state networks in the course of aging—differential insights from studies across the lifespan vs. amongst the old. Pflügers Arch – Eur J Physiol. 2021;473:793–803.
Coelho A, Fernandes HM, Magalhães R, Moreira PS, Marques P, Soares JM, et al. Reorganization of brain structural networks in aging: a longitudinal study. J Neurosci Res. 2021;99:1354–76.
Ng KK, Lo JC, Lim JKW, Chee MWL, Zhou J. Reduced functional segregation between the default mode network and the executive control network in healthy older adults: a longitudinal study. NeuroImage 2016;133:321–30.
Betzel RF, Byrge L, He Y, Goñi J, Zuo X-N, Sporns O. Changes in structural and functional connectivity among resting-state networks across the human lifespan. NeuroImage. 2014;102:345–57.
Chan MY, Park DC, Savalia NK, Petersen SE, Wig GS. Decreased segregation of brain systems across the healthy adult lifespan. Proc Natl Acad Sci USA. 2014;111:E4997–E5006.
Geerligs L, Renken RJ, Saliasi E, Maurits NM, Lorist MM. A brain-wide study of age-related changes in functional connectivity. Cereb Cortex. 2014;25:1987–99.
Grady C, Sarraf S, Saverino C, Campbell K. Age differences in the functional interactions among the default, frontoparietal control, and dorsal attention networks. Neurobiol Aging. 2016;41:159–72.
Hughes C, Faskowitz J, Cassidy BS, Sporns O, Krendl AC. Aging relates to a disproportionately weaker functional architecture of brain networks during rest and task states. NeuroImage. 2020;209:116521.
Setton R, Mwilambwe-Tshilobo L, Girn M, Lockrow AW, Baracchini G, Hughes C, et al. Age differences in the functional architecture of the human brain. Cereb Cortex. 2022;33:114–34.
Zonneveld HI, Pruim RH, Bos D, Vrooman HA, Muetzel RL, Hofman A, et al. Patterns of functional connectivity in an aging population: the Rotterdam Study. Neuroimage. 2019;189:432–44.
Buckner RL. Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron. 2004;44:195–208.
Park DC, Reuter-Lorenz P. The adaptive brain: aging and neurocognitive scaffolding. Annu Rev Psychol. 2009;60:173–96.
Morcom AM, Johnson W. Neural reorganization and compensation in aging. J Cogn Neurosci. 2015;27:1275–85.
Zhu Z, Johnson NF, Kim C, Gold BT. Reduced frontal cortex efficiency is associated with lower white matter integrity in aging. Cereb Cortex. 2013;25:138–46.
Zhu Z, Johnson NF, Kim C, Gold BT. Reduced frontal cortex efficiency is associated with lower white matter integrity in aging. Cereb Cortex. 2015;25:138–46.
Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci. 2019;22:343–52.
Buch AM, Liston C. Dissecting diagnostic heterogeneity in depression by integrating neuroimaging and genetics. Neuropsychopharmacology. 2021;46:156–75.
Nguyen TD, Harder A, Xiong Y, Kowalec K, Hagg S, Cai N, et al. Genetic heterogeneity and subtypes of major depression. Mol Psychiatry. 2022;27:1667–75.
Taylor WD, Aizenstein HJ, Alexopoulos GS. The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry. 2013;18:963–74.
Bellis MA, Hughes K, Ford K, Ramos Rodriguez G, Sethi D, Passmore J. Life course health consequences and associated annual costs of adverse childhood experiences across Europe and North America: a systematic review and meta-analysis. Lancet Public Health. 2019;4:e517–e28.
Saleh A, Potter GG, McQuoid DR, Boyd B, Turner R, MacFall JR, et al. Effects of early life stress on depression, cognitive performance and brain morphology. Psychol Med. 2017;47:171–81.
Meaney MJ. Maternal care, gene expression, and the transmission of individual differences in stress reactivity across generations. Ann Rev Neurosci. 2001;24:1161–92.
Iob E, Lacey R, Steptoe A. Adverse childhood experiences and depressive symptoms in later life: longitudinal mediation effects of inflammation. Brain Behav Immun. 2020;90:97–107.
Cheong EV, Sinnott C, Dahly D, Kearney PM. Adverse childhood experiences (ACEs) and later-life depression: perceived social support as a potential protective factor. BMJ Open. 2017;7:e013228.
Zannas AS, McQuoid DR, Steffens DC, Chrousos GP, Taylor WD. Stressful life events, perceived stress, and 12-month course of geriatric depression: direct effects and moderation by the 5-HTTLPR and COMT Val158Met polymorphisms. Stress. 2012;15:425–34.
Kendler KS, Karkowski LM, Prescott CA. Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry. 1999;156:837–41.
Hayward RD, Taylor WD, Smoski MJ, Steffens DC, Payne ME. Association of five-factor model personality domains and facets with presence, onset, and treatment outcomes of major depression in older adults. Am J Geriatr Psychiatry. 2013;21:88–96.
Manning KJ, Chan G, Steffens DC. Neuroticism traits selectively impact long term illness course and cognitive decline in late-life depression. Am J Geriatr Psychiatry. 2017;25:220–9.
Steffens DC, McQuoid DR, Smoski MJ, Potter GG. Clinical outcomes of older depressed patients with and without comorbid neuroticism. Int Psychogeriatr. 2013;25:1985–90.
Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry. 2018;75:336–46.
Soares CN, Zitek B. Reproductive hormone sensitivity and risk for depression across the female life cycle: a continuum of vulnerability? J Psychiatry Neurosci. 2008;33:331–43.
Payne JL, Maguire J. Pathophysiological mechanisms implicated in postpartum depression. Front Neuroendocrinol. 2019;52:165–80.
Arevalo MA, Azcoitia I, Garcia-Segura LM. The neuroprotective actions of oestradiol and oestrogen receptors. Nat Rev Neurosci. 2015;16:17–29.
Georgakis MK, Thomopoulos TP, Diamantaras AA, Kalogirou EI, Skalkidou A, Daskalopoulou SS, et al. Association of age at menopause and duration of reproductive period with depression after menopause: a systematic review and meta-analysis. JAMA Psychiatry. 2016;73:139–49.
Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007;69:1074–83.
Stein MB, Jain S, Giacino JT, Levin H, Dikmen S, Nelson LD, et al. Risk of posttraumatic stress disorder and major depression in civilian patients after mild traumatic brain injury: a TRACK-TBI study. JAMA Psychiatry. 2019;76:249–58.
Milaneschi Y, Simmons WK, van Rossum EFC, Penninx BW. Depression and obesity: evidence of shared biological mechanisms. Mol Psychiatry. 2019;24:18–33.
Taylor WD, McQuoid DR, Krishnan KR. Medical comorbidity in late-life depression. Int J Geriatr Psychiatry. 2004;19:935–43.
Griffin SC, Young JR, Naylor JC, Allen KD, Beckham JC, Calhoun PS. Reciprocal effects between depressive symptoms and pain in veterans over 50 years of age or older. Pain Med. 2022;23:295–304.
Alexopoulos GS, Morimoto SS. The inflammation hypothesis in geriatric depression. Int J Geriatr Psychiatry. 2011;26:1109–18.
Dantzer R, O’Connor JC, Lawson MA, Kelley KW. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology. 2011;36:426–36.
Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16:22–34.
Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 2001;58:445–52.
Grigoleit JS, Kullmann JS, Wolf OT, Hammes F, Wegner A, Jablonowski S, et al. Dose-dependent effects of endotoxin on neurobehavioral functions in humans. PLoS ONE. 2011;6:e28330.
Kohler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand. 2017;135:373–87.
Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446–57.
Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry. 2009;66:287–92.
Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171–86.
Sartori AC, Vance DE, Slater LZ, Crowe M. The impact of inflammation on cognitive function in older adults: implications for healthcare practice and research. J Neurosci Nurs. 2012;44:206–17.
Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244–54.
Franceschi C, Zaikin A, Gordleeva S, Ivanchenko M, Bonifazi F, Storci G, et al. Inflammaging 2018: an update and a model. Semin Immunol. 2018;40:1–5.
Meszaros A, Molnar K, Nogradi B, Hernadi Z, Nyul-Toth A, Wilhelm I, et al. Neurovascular inflammaging in health and disease. Cells. 2020;9:1614.
Nair D, Cukor D, Taylor WD, Cavanaugh KL. Applying a biopsychosocial framework to achieve durable behavior change in kidney disease. Semin Nephrol. 2021;41:487–504.
Rutledge T, Linke SE, Krantz DS, Johnson BD, Bittner V, Eastwood JA, et al. Comorbid depression and anxiety symptoms as predictors of cardiovascular events: results from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE) study. Psychosom Med. 2009;71:958–64.
Drosselmeyer J, Jacob L, Rathmann W, Rapp MA, Kostev K. Depression risk in patients with late-onset rheumatoid arthritis in Germany. Qual Life Res. 2017;26:437–43.
Benros ME, Waltoft BL, Nordentoft M, Ostergaard SD, Eaton WW, Krogh J, et al. Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMA Psychiatry. 2013;70:812–20.
Luning Prak ET, Brooks T, Makhoul W, Beer JC, Zhao L, Girelli T, et al. No increase in inflammation in late-life major depression screened to exclude physical illness. Transl Psychiatry. 2022;12:118.
Quan N, Banks WA. Brain-immune communication pathways. Brain Behav Immun. 2007;21:727–35.
Yirmiya R, Rimmerman N, Reshef R. Depression as a microglial disease. Trends Neurosci. 2015;38:637–58.
Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46–56.
Dilger RN, Johnson RW. Aging, microglial cell priming, and the discordant central inflammatory response to signals from the peripheral immune system. J Leukoc Biol. 2008;84:932–9.
Frank MG, Weber MD, Watkins LR, Maier SF. Stress-induced neuroinflammatory priming: a liability factor in the etiology of psychiatric disorders. Neurobiol Stress. 2016;4:62–70.
Haroon E, Miller AH, Sanacora G. Inflammation, glutamate, and glia: a trio of trouble in mood disorders. Neuropsychopharmacology. 2017;42:193–215.
Haroon E, Felger JC, Woolwine BJ, Chen X, Parekh S, Spivey JR, et al. Age-related increases in basal ganglia glutamate are associated with TNF, reduced motivation and decreased psychomotor speed during IFN-alpha treatment: preliminary findings. Brain Behav Immun. 2015;46:17–22.
Haroon E, Woolwine BJ, Chen X, Pace TW, Parekh S, Spivey JR, et al. IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy. Neuropsychopharmacology. 2014;39:1777–85.
Capuron L, Schroecksnadel S, Feart C, Aubert A, Higueret D, Barberger-Gateau P, et al. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry. 2011;70:175–82.
Felger JC, Mun J, Kimmel HL, Nye JA, Drake DF, Hernandez CR, et al. Chronic interferon-alpha decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman primates. Neuropsychopharmacology. 2013;38:2179–87.
Seaman KL, Smith CT, Juarez EJ, Dang LC, Castrellon JJ, Burgess LL, et al. Differential regional decline in dopamine receptor availability across adulthood: linear and nonlinear effects of age. Hum Brain Mapp. 2019;40:3125–38.
Karrer TM, Josef AK, Mata R, Morris ED, Samanez-Larkin GR. Reduced dopamine receptors and transporters but not synthesis capacity in normal aging adults: a meta-analysis. Neurobiol Aging. 2017;57:36–46.
Gu Y, Vorburger R, Scarmeas N, Luchsinger JA, Manly JJ, Schupf N, et al. Circulating inflammatory biomarkers in relation to brain structural measurements in a non-demented elderly population. Brain Behav Immun. 2017;65:150–60.
Kraynak TE, Marsland AL, Wager TD, Gianaros PJ. Functional neuroanatomy of peripheral inflammatory physiology: A meta-analysis of human neuroimaging studies. Neurosci Biobehav Rev. 2018;94:76–92.
Enache D, Pariante CM, Mondelli V. Markers of central inflammation in major depressive disorder: a systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain Behav Immun. 2019;81:24–40.
Torres-Platas SG, Cruceanu C, Chen GG, Turecki G, Mechawar N. Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides. Brain Behav Immun. 2014;42:50–9.
Vogelzangs N, Comijs HC, Oude Voshaar RC, Stek ML, Penninx BW. Late-life depression symptom profiles are differentially associated with immunometabolic functioning. Brain Behav Immun. 2014;41:109–15.
Uher R, Tansey KE, Dew T, Maier W, Mors O, Hauser J, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry. 2014;171:1278–86.
Chamberlain SR, Cavanagh J, de Boer P, Mondelli V, Jones DNC, Drevets WC, et al. Treatment-resistant depression and peripheral C-reactive protein. Br J Psychiatry. 2019;214:11–9.
Strawbridge R, Arnone D, Danese A, Papadopoulos A, Herane Vives A, Cleare AJ. Inflammation and clinical response to treatment in depression: a meta-analysis. Eur Neuropsychopharmacol. 2015;25:1532–43.
Kohler CA, Evangelou E, Stubbs B, Solmi M, Veronese N, Belbasis L, et al. Mapping risk factors for depression across the lifespan: An umbrella review of evidence from meta-analyses and Mendelian randomization studies. J Psychiatr Res. 2018;103:189–207.
Liu JJ, Wei YB, Strawbridge R, Bao Y, Chang S, Shi L, et al. Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis. Mol Psychiatry. 2020;25:339–50.
Kohler-Forsberg O, C NL, Hjorthoj C, Nordentoft M, Mors O, Benros ME. Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. Acta Psychiatr Scand. 2019;139:404–19.
Kohler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71:1381–91.
Bavaresco DV, Uggioni MLR, Ferraz SD, Marques RMM, Simon CS, Dagostin VS, et al. Efficacy of infliximab in treatment-resistant depression: A systematic review and meta-analysis. Pharm Biochem Behav. 2020;188:172838.
Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31–41.
Dunjic-Kostic B, Ivkovic M, Radonjic NV, Petronijevic ND, Pantovic M, Damjanovic A, et al. Melancholic and atypical major depression—connection between cytokines, psychopathology and treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2013;43:1–6.
Zimmerman B, Rypma B, Gratton G, Fabiani M. Age-related changes in cerebrovascular health and their effects on neural function and cognition: a comprehensive review. Psychophysiology. 2021;58:e13796.
Mustapha M, Nassir C, Aminuddin N, Safri AA, Ghazali MM. Cerebral small vessel disease (CSVD)—lessons from the animal models. Front Physiol. 2019;10:1317.
Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. ‘Vascular depression’ hypothesis. Arch Gen Psychiatry. 1997;54:915–22.
Krishnan KRR, Hays JC, Blazer DG. MRI-defined vascular depression. Am J Psychiatry. 1997;154:497–501.
Blochl M, Schaare HL, Kunzmann U, Nestler S. The age-dependent association between vascular risk factors and depressed mood. J Gerontol B Psychol Sci Soc Sci. 2022;77:284–94.
Krishnan KRR, Tayor WD, McQuoid DR, MacFall JR, Payne ME, Provenzale JM, et al. Clinical characteristics of magnetic resonance imaging-defined subcortical ischemic depression. Biol Psychiatry. 2004;55:390–7.
Fang Y, Qin T, Liu W, Ran L, Yang Y, Huang H, et al. Cerebral small-vessel disease and risk of incidence of depression: a meta-analysis of longitudinal cohort studies. J Am Heart Assoc. 2020;9:e016512.
Smagula SF, Aizenstein HJ. Brain structural connectivity in late-life major depressive disorder. Biol Psychiatry Cogn Neurosci Neuroimaging. 2016;1:271–7.
Herrmann LL, Le Masurier M, Ebmeier KP. White matter hyperintensities in late life depression: a systematic review. J Neurol Neurosurg Psychiatry. 2008;79:619–24.
Salo KI, Scharfen J, Wilden ID, Schubotz RI, Holling H. Confining the concept of vascular depression to late-onset depression: a meta-analysis of MRI-defined hyperintensity burden in major depressive disorder and bipolar disorder. Front Psychol. 2019;10:1241.
Meinert S, Nowack N, Grotegerd D, Repple J, Winter NR, Abheiden I, et al. Association of brain white matter microstructure with cognitive performance in major depressive disorder and healthy controls: a diffusion-tensor imaging study. Mol Psychiatry. 2022;27:1103–10.
Taylor WD, Payne ME, Krishnan KRR, Wagner HR, Provenzale JM, Steffens DC, et al. Evidence of white matter tract disruption in MRI hyperintensities. Biol Psychiatry. 2001;50:179–83.
Taylor WD, Zhao Z, Ashley-Koch A, Payne ME, Steffens DC, Krishnan RR, et al. Fiber tract-specific white matter lesion severity Findings in late-life depression and by AGTR1 A1166C genotype. Hum Brain Mapp. 2013;34:295–303.
Sheline YI, Price JL, Vaishnavi SN, Mintun MA, Barch DM, Epstein AA, et al. Regional white matter hyperintensity burden in automated segmentation distinguishes late-life depressed subjects from comparison subjects matched for vascular risk factors. Am J Psychiatry. 2008;165:524–32.
Taylor WD, Kudra K, Zhao Z, Steffens DC, MacFall JR. Cingulum bundle white matter lesions influence antidepressant response in late-life depression: a pilot study. J Affect Disord. 2014;162:8–11.
Wen MC, Steffens DC, Chen MK, Zainal NH. Diffusion tensor imaging studies in late-life depression: systematic review and meta-analysis. Int J Geriatr Psychiatry. 2014;29:1173–84.
Zanon Zotin MC, Sveikata L, Viswanathan A, Yilmaz P. Cerebral small vessel disease and vascular cognitive impairment: from diagnosis to management. Curr Opin Neurol. 2021;34:246–57.
Arola A, Levanen T, Laakso HM, Pitkanen J, Koikkalainen J, Lotjonen J, et al. Neuropsychiatric symptoms are associated with exacerbated cognitive impairment in covert cerebral small vessel disease. J Int Neuropsychol Soc. 2022; 1–8. https://doi.org/10.1017/S1355617722000480.
Butters MA, Young JB, Lopez O, Aizenstein HJ, Mulsant BH, Reynolds CF 3rd, et al. Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues Clin Neurosci. 2008;10:345–57.
Taylor WD, Steffens DC, MacFall JR, McQuoid DR, Payne ME, Provenzale JM, et al. White matter hyperintensity progression and late-life depression outcomes. Arch Gen Psychiatry. 2003;60:1090–6.
Alexopoulos GS. Mechanisms and treatment of late-life depression. Transl Psychiatry. 2019;9:188.
Sheline YI, Pieper CF, Barch DM, Welsh-Bohmer K, McKinstry RC, MacFall JR, et al. Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial. Arch Gen Psychiatry. 2010;67:277–85.
Boutzoukas EM, O’Shea A, Kraft JN, Hardcastle C, Evangelista ND, Hausman HK, et al. Higher white matter hyperintensity load adversely affects pre-post proximal cognitive training performance in healthy older adults. Geroscience. 2022;44:1441–55.
Cui K, Song R, Xu H, Shang Y, Qi X, Buchman AS, et al. Association of cardiovascular risk burden with risk and progression of disability: mediating role of cardiovascular disease and cognitive decline. J Am Heart Assoc. 2020;9:e017346.
Hou Y, Li Y, Yang S, Qin W, Yang L, Hu W. Gait impairment and upper extremity disturbance are associated with total magnetic resonance imaging cerebral small vessel disease burden. Front Aging Neurosci. 2021;13:640844.
Stewart R. Cardiovascular disease and frailty: what are the mechanistic links? Clin Chem. 2019;65:80–6.
Harshfield EL, Pennells L, Schwartz JE, Willeit P, Kaptoge S, Bell S, et al. Association between depressive symptoms and incident cardiovascular diseases. J Am Med Assoc. 2020;324:2396–405.
Zahodne LB, Gilsanz P, Glymour MM, Gibbons LE, Brewster P, Hamilton J, et al. Comparing variability, severity, and persistence of depressive symptoms as predictors of future stroke risk. Am J Geriatr Psychiatry. 2017;25:120–8.
Jorm AF, Jolley D. The incidence of dementia: a meta-analysis. Neurology. 1998;51:728–33.
Dotson VM, Beydoun MA, Zonderman AB. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology. 2010;75:27–34.
Barnes DE, Yaffe K, Byers AL, McCormick M, Schaefer C, Whitmer RA. Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia. Arch Gen Psychiatry. 2012;69:493–8.
Leung DKY, Chan WC, Spector A, Wong GHY. Prevalence of depression, anxiety, and apathy symptoms across dementia stages: a systematic review and meta-analysis. Int J Geriatr Psychiatry. 2021;36:1330–44.
Wilson RS, Capuano AW, Boyle PA, Hoganson GM, Hizel LP, Shah RC, et al. Clinical-pathologic study of depressive symptoms and cognitive decline in old age. Neurology. 2014;83:702–9.
Mirza SS, Wolters FJ, Swanson SA, Koudstaal PJ, Hofman A, Tiemeier H, et al. 10-year trajectories of depressive symptoms and risk of dementia: a population-based study. Lancet Psychiatry. 2016;3:628–35.
Krishnan KR, Tupler LA, Ritchie JCJ, McDonald WM, Knight DL, Nemeroff CB, et al. Apolipoprotein E-e4 frequency in geriatric depression. Biol Psychiatry. 1996;40:69–71.
Steffens DC, Norton MC, Hart AD, Skoog I, Corcoran C, Breitner JC. Apolipoprotein E genotype and major depression in a community of older adults. The Cache County Study. Psychol Med. 2003;33:541–7.
Harerimana NV, Liu Y, Gerasimov ES, Duong D, Beach TG, Reiman EM, et al. Genetic evidence supporting a causal role of depression in Alzheimer’s disease. Biol Psychiatry. 2022;92:25–33.
Mahgoub N, Alexopoulos GS. Amyloid hypothesis: is there a role for antiamyloid treatment in late-life depression? Am J Geriatr Psychiatry. 2016;24:239–47.
Wu KY, Hsiao IT, Chen CS, Chen CH, Hsieh CJ, Wai YY, et al. Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41:714–22.
Wu KY, Liu CY, Chen CS, Chen CH, Hsiao IT, Hsieh CJ, et al. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study. Eur J Nucl Med Mol Imaging. 2016;43:1067–76.
Hyung WSW, Kang J, Kim J, Lee S, Youn H, Ham BJ, et al. Cerebral amyloid accumulation is associated with distinct structural and functional alterations in the brain of depressed elders with mild cognitive impairment. J Affect Disord. 2021;281:459–66.
Wang SM, Kim NY, Um YH, Kang DW, Na HR, Lee CU, et al. Default mode network dissociation linking cerebral beta amyloid retention and depression in cognitively normal older adults. Neuropsychopharmacology. 2021;46:2180–7.
Mackin RS, Insel PS, Landau S, Bickford D, Morin R, Rhodes E, et al. Late-life depression is associated with reduced cortical amyloid burden: findings from the Alzheimer’s disease neuroimaging initiative depression project. Biol Psychiatry. 2021;89:757–65.
Babulal GM, Roe CM, Stout SH, Rajasekar G, Wisch JK, Benzinger TLS, et al. Depression is associated with tau and not amyloid positron emission tomography in cognitively normal adults. J Alzheimers Dis. 2020;74:1045–55.
Alexopoulos GS, Kiosses DN, Heo M, Murphy CF, Shanmugham B, Gunning-Dixon F. Executive dysfunction and the course of geriatric depression. Biol Psychiatry. 2005;58:204–10.
Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, et al. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010;18:136–45.
Taylor WD, Boyd BD, Elson D, Andrews P, Albert K, Vega J, et al. Preliminary evidence that cortical amyloid burden predicts poor response to antidepressant medication treatment in cognitively intact individuals with late-life depression. Am J Geriatr Psychiatry. 2021;29:448–57.
Li P, Hsiao IT, Liu CY, Chen CH, Huang SY, Yen TC, et al. Beta-amyloid deposition in patients with major depressive disorder with differing levels of treatment resistance: a pilot study. EJNMMI Res. 2017;7:24.
Morimoto SS, Altizer RA, Gunning FM, Hu W, Liu J, Cote SE, et al. Targeting cognitive control deficits with neuroplasticity-based computerized cognitive remediation in patients with geriatric major depression: a randomized, double-blind, controlled trial. Am J Geriatr Psychiatry. 2020;28:971–80.
Weintraub D, Aarsland D, Chaudhuri KR, Dobkin RD, Leentjens AF, Rodriguez-Violante M, et al. The neuropsychiatry of Parkinson’s disease: advances and challenges. Lancet Neurol. 2022;21:89–102.
Wang S, Mao S, Xiang D, Fang C. Association between depression and the subsequent risk of Parkinson’s disease: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2018;86:186–92.
Rotter A, Lenz B, Pitsch R, Richter-Schmidinger T, Kornhuber J, Rhein C. Alpha-synuclein RNA expression is increased in major depression. Int J Mol Sci. 2019;20:2029.
Bruno D, Reichert Plaska C, Clark DPA, Zetterberg H, Blennow K, Verbeek MM, et al. CSF alpha-synuclein correlates with CSF neurogranin in late-life depression. Int J Neurosci. 2021;131:357–61.
Khan SS, Singer BD, Vaughan DE. Molecular and physiological manifestations and measurement of aging in humans. Aging Cell. 2017;16:624–33.
Christman S, Bermudez C, Hao L, Landman BA, Boyd B, Albert K, et al. Accelerated brain aging predicts impaired cognitive performance and greater disability in geriatric but not midlife adult depression. Transl Psychiatry. 2020;10:317.
Cole JH, Marioni RE, Harris SE, Deary IJ. Brain age and other bodily ‘ages’: implications for neuropsychiatry. Mol Psychiatry. 2019;24:266–81.
Miller MW, Sadeh N. Traumatic stress, oxidative stress and post-traumatic stress disorder: neurodegeneration and the accelerated-aging hypothesis. Mol Psychiatry. 2014;19:1156–62.
Han LKM, Aghajani M, Clark SL, Chan RF, Hattab MW, Shabalin AA, et al. Epigenetic aging in major depressive disorder. Am J Psychiatry. 2018;175:774–82.
Robinson O, Chadeau Hyam M, Karaman I, Climaco Pinto R, Ala-Korpela M, Handakas E, et al. Determinants of accelerated metabolomic and epigenetic aging in a UK cohort. Aging Cell. 2020;19:e13149.
Dunlop K, Victoria LW, Downar J, Gunning FM, Liston C. Accelerated brain aging predicts impulsivity and symptom severity in depression. Neuropsychopharmacology. 2021;46:911–9.
Han LKM, Dinga R, Hahn T, Ching CRK, Eyler LT, Aftanas L, et al. Brain aging in major depressive disorder: results from the ENIGMA major depressive disorder working group. Mol Psychiatry. 2021;26:5124–39.
Han LKM, Dinga R, Leenings R, Hahn T, Cole JH, Aftanas LI, et al. A large-scale ENIGMA multisite replication study of brain age in depression. Neuroimage Rep. 2022;2:100149.
Taylor WD. Coexisting depression and frailty as an accelerated aging phenotype of late-life depression. Int Psychogeriatr. 2023;1–7. https://doi.org/10.1017/S1041610223000170.
Brown PJ, Wall MM, Chen C, Levine ME, Yaffe K, Roose SP, et al. Biological age, not chronological age, is associated with late-life depression. J Gerontol A Biol Sci Med Sci. 2018;73:1370–6.
Diniz BS, Mulsant BH, Reynolds CF 3rd, Blumberger DM, Karp JF, Butters MA, et al. Association of molecular senescence markers in late-life depression with clinical characteristics and treatment outcome. JAMA Netw Open. 2022;5:e2219678.
Ballester PL, Suh JS, Nogovitsyn N, Hassel S, Strother SC, Arnott SR, et al. Accelerated brain aging in major depressive disorder and antidepressant treatment response: a CAN-BIND report. Neuroimage Clin. 2021;32:102864.
Han LKM, Verhoeven JE, Tyrka AR, Penninx B, Wolkowitz OM, Mansson KNT, et al. Accelerating research on biological aging and mental health: current challenges and future directions. Psychoneuroendocrinology. 2019;106:293–311.
Elliott ML, Caspi A, Houts RM, Ambler A, Broadbent JM, Hancox RJ, et al. Disparities in the pace of biological aging among midlife adults of the same chronological age have implications for future frailty risk and policy. Nat Aging. 2021;1:295–308.
Fried LP, Cohen AA, Xue QL, Walston J, Bandeen-Roche K, Varadhan R. The physical frailty syndrome as a transition from homeostatic symphony to cacophony. Nat Aging. 2021;1:36–46.
Brown PJ, Roose SP, Zhang J, Wall M, Rutherford BR, Ayonayon HN, et al. Inflammation, depression, and slow gait: a high mortality phenotype in later life. J Gerontol A Biol Sci Med Sci. 2016;71:221–7.
Brown PJ, Ciarleglio A, Roose SP, Montes Garcia C, Chung S, Fernandes S, et al. Frailty and depression in late life: a high-risk comorbidity with distinctive clinical presentation and poor antidepressant response. J Gerontol A Biol Sci Med Sci. 2022;77:1055–62.
Brown PJ, Roose SP, O’Boyle KR, Ciarleglio A, Maas B, Igwe KC, et al. Frailty and its correlates in adults with late life depression. Am J Geriatr Psychiatry. 2020;28:145–54.
Lever-van Milligen BA, Lamers F, Smit JH, Penninx BW. Six-year trajectory of objective physical function in persons with depressive and anxiety disorders. Depress Anxiety. 2017;34:188–97.
Rutherford BR, Taylor WD, Brown PJ, Sneed JR, Roose SP. Biological aging and the future of geriatric psychiatry. J Gerontol A Biol Sci Med Sci. 2017;72:343–52.
McEwen BS, Karatsoreos IN. Sleep deprivation and circadian disruption: stress, allostasis, and allostatic load. Sleep Med Clin. 2015;10:1–10.
Belvederi Murri M, Pariante C, Mondelli V, Masotti M, Atti AR, Mellacqua Z, et al. HPA axis and aging in depression: systematic review and meta-analysis. Psychoneuroendocrinology. 2014;41:46–62.
Gianaros PJ, Sheu LK, Uyar F, Koushik J, Jennings JR, Wager TD, et al. A brain phenotype for stressor-evoked blood pressure reactivity. J Am Heart Assoc. 2017;6:e006053.
Bagley SL, Weaver TL, Buchanan TW. Sex differences in physiological and affective responses to stress in remitted depression. Physiol Behav. 2011;104:180–6.
Admon R, Holsen LM, Aizley H, Remington A, Whitfield-Gabrieli S, Goldstein JM, et al. Striatal hypersensitivity during stress in remitted individuals with recurrent depression. Biol Psychiatry. 2015;78:67–76.
Zhong M, Wang X, Xiao J, Yi J, Zhu X, Liao J, et al. Amygdala hyperactivation and prefrontal hypoactivation in subjects with cognitive vulnerability to depression. Biol Psychol. 2011;88:233–42.
Ahrens T, Deuschle M, Krumm B, van der Pompe G, den Boer JA, Lederbogen F. Pituitary-adrenal and sympathetic nervous system responses to stress in women remitted from recurrent major depression. Psychosom Med. 2008;70:461–7.
McEwen BS, Akil H. Revisiting the stress concept: implications for affective disorders. J Neurosci. 2020;40:12–21.
Geerlings MI, Sigurdsson S, Eiriksdottir G, Garcia ME, Harris TB, Gudnason V, et al. Salivary cortisol, brain volumes, and cognition in community-dwelling elderly without dementia. Neurology. 2015;85:976–83.
Lupien SJ, de Leon M, de Santi S, Convit A, Tarshish C, Nair NPV, et al. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat Neurosci. 1998;1:69–73.
Cox SR, Bastin ME, Ferguson KJ, Maniega SM, MacPherson SE, Deary IJ, et al. Brain white matter integrity and cortisol in older men: the Lothian Birth Cohort 1936. Neurobiol Aging. 2015;36:257–64.
Taylor WD, McQuoid DR, Payne ME, Zannas AS, MacFall JR, Steffens DC. Hippocampus atrophy and the longitudinal course of late-life depression. Am J Geriatr Psychiatry. 2014;22:1504–12.
Wertz J, Caspi A, Ambler A, Broadbent J, Hancox RJ, Harrington H, et al. Association of history of psychopathology with accelerated aging at midlife. JAMA Psychiatry. 2021;78:530–9.
Patel K, Abdool PS, Rajji TK, Mulsant BH. Pharmacotherapy of major depression in late life: what is the role of new agents? Expert Opin Pharmacother. 2017;18:599–609.
Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry. 2011;72:1660–8.
Calati R, Salvina Signorelli M, Balestri M, Marsano A, De Ronchi D, Aguglia E, et al. Antidepressants in elderly: metaregression of double-blind, randomized clinical trials. J Affect Disord. 2013;147:1–8.
Kok RM, Nolen WA, Heeren TJ. Efficacy of treatment in older depressed patients: a systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants. J Affect Disord. 2012;141:103–15.
Karim HT, Andreescu C, Tudorascu D, Smagula SF, Butters MA, Karp JF, et al. Intrinsic functional connectivity in late-life depression: trajectories over the course of pharmacotherapy in remitters and non-remitters. Mol Psychiatry. 2017;22:450–7.
Disabato BM, Morris C, Hranilovich J, D’Angelo GM, Zhou G, Wu N, et al. Comparison of brain structural variables, neuropsychological factors, and treatment outcome in early-onset versus late-onset late-life depression. Am J Geriatr Psychiatry. 2014;22:1039–46.
Reynolds CF 3rd, Dew MA, Frank E, Begley AE, Miller MD, Cornes C, et al. Effects of age at onset of first lifetime episode of recurrent major depression on treatment response and illness course in elderly patients. Am J Psychiatry. 1998;155:795–9.
Kok RM, Reynolds CF 3rd. Management of depression in older adults: a review. J Am Med Assoc. 2017;317:2114–22.
Lenze EJ, Mulsant BH, Roose SP, Lavretsky H, Reynolds CF3rd, Blumberger DM, et al. Antidepressant augmentation versus switch in treatment-resistant geriatric depression. N Engl J Med. 2023;388:1067–79.
Lavretsky H, Reinlieb M, St Cyr N, Siddarth P, Ercoli LM, Senturk D. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172:561–9.
Cooper C, Katona C, Lyketsos K, Blazer D, Brodaty H, Rabins P, et al. A systematic review of treatments for refractory depression in older people. Am J Psychiatry. 2011;168:681–8.
Lenze EJ, Mulsant BH, Blumberger DM, Karp JF, Newcomer JW, Anderson SJ, et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:2404–12.
Buchalter ELF, Oughli HA, Lenze EJ, Dixon D, Miller JP, Blumberger DM, et al. Predicting remission in late-life major depression: a clinical algorithm based upon past treatment history. J Clin Psychiatry. 2019;80:18m12483.
George D, Galvez V, Martin D, Kumar D, Leyden J, Hadzi-Pavlovic D, et al. Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression. Am J Geriatr Psychiatry. 2017;25:1199–209.
Lipsitz O, Di Vincenzo JD, Rodrigues NB, Cha DS, Lee Y, Greenberg D, et al. Safety, tolerability, and real-world effectiveness of intravenous ketamine in older adults with treatment-resistant depression: a case series. Am J Geriatr Psychiatry. 2021;29:899–913.
Subramanian S, Lenze EJ. Ketamine for depression in older adults. Am J Geriatr Psychiatry. 2021;29:914–6.
Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Morrison RL, et al. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3. Am J Geriatr Psychiatry. 2020;28:121–41.
Prudic J, Olfson M, Marcus SC, Fuller RB, Sackeim HA. Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry. 2004;55:301–12.
Dols A, Bouckaert F, Sienaert P, Rhebergen D, Vansteelandt K, Ten Kate M, et al. Early- and late-onset depression in late life: a prospective study on clinical and structural brain characteristics and response to electroconvulsive therapy. Am J Geriatr Psychiatry. 2017;25:178–89.
Prudic J, Haskett RF, McCall WV, Isenberg K, Cooper T, Rosenquist PB, et al. Pharmacological strategies in the prevention of relapse after electroconvulsive therapy. J ECT. 2013;29:3–12.
Kumar S, Mulsant BH, Liu AY, Blumberger DM, Daskalakis ZJ, Rajji TK. Systematic review of cognitive effects of electroconvulsive therapy in late-life depression. Am J Geriatr Psychiatry. 2016;24:547–65.
Tor PC, Bautovich A, Wang MJ, Martin D, Harvey SB, Loo C. A systematic review and meta-analysis of brief versus ultrabrief right unilateral electroconvulsive therapy for depression. J Clin Psychiatry. 2015;76:e1092–8.
Kellner CH, Husain MM, Knapp RG, McCall WV, Petrides G, Rudorfer MV, et al. Right unilateral ultrabrief pulse ECT in geriatric depression: phase 1 of the PRIDE study. Am J Psychiatry. 2016;173:1101–9.
Lisanby SH, McClintock SM, Alexopoulos G, Bailine SH, Bernhardt E, Briggs MC, et al. Neurocognitive effects of combined electroconvulsive therapy (ECT) and venlafaxine in geriatric depression: phase 1 of the PRIDE study. Am J Geriatr Psychiatry. 2020;28:304–16.
Kellner CH, Husain MM, Knapp RG, McCall WV, Petrides G, Rudorfer MV, et al. A novel strategy for continuation ECT in geriatric depression: phase 2 of the PRIDE study. Am J Psychiatry. 2016;173:1110–8.
McCall WV, Lisanby SH, Rosenquist PB, Dooley M, Husain MM, Knapp RG, et al. Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients: a randomized clinical trial. J Psychiatr Res. 2018;97:65–9.
Trevizol AP, Goldberger KW, Mulsant BH, Rajji TK, Downar J, Daskalakis ZJ, et al. Unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant late-life depression. Int J Geriatr Psychiatry. 2019;34:822–7.
Liston C, Chen AC, Zebley BD, Drysdale AT, Gordon R, Leuchter B, et al. Default mode network mechanisms of transcranial magnetic stimulation in depression. Biol Psychiatry. 2014;76:517–26.
van Rooij SJH, Riva-Posse P, McDonald WM. The efficacy and safety of neuromodulation treatments in late-life depression. Curr Treat Options Psychiatry. 2020;7:337–48.
Jorge RE, Moser DJ, Acion L, Robinson RG. Treatment of vascular depression using repetitive transcranial magnetic stimulation. Arch Gen Psychiatry. 2008;65:268–76.
Overvliet GM, Jansen RAC, van Balkom A, van Campen DC, Oudega ML, van der Werf YD, et al. Adverse events of repetitive transcranial magnetic stimulation in older adults with depression, a systematic review of the literature. Int J Geriatr Psychiatry. 2021;36:383–92.
Kaster TS, Daskalakis ZJ, Noda Y, Knyahnytska Y, Downar J, Rajji TK, et al. Efficacy, tolerability, and cognitive effects of deep transcranial magnetic stimulation for late-life depression: a prospective randomized controlled trial. Neuropsychopharmacology. 2018;43:2231–8.
Mosimann UP, Marre SC, Werlen S, Schmitt W, Hess CW, Fisch HU, et al. Antidepressant effects of repetitive transcranial magnetic stimulation in the elderly: correlation between effect size and coil-cortex distance. Arch Gen Psychiatry. 2002;59:560–1.
Blumberger DM, Mulsant BH, Thorpe KE, McClintock SM, Konstantinou GN, Lee HH, et al. Effectiveness of standard sequential bilateral repetitive transcranial magnetic stimulation vs bilateral theta burst stimulation in older adults with depression: the FOUR-D randomized noninferiority clinical trial. JAMA Psychiatry. 2022;79:1065–73.
Ryff CD, Friedman EM, Morozink JA, Tsenkova V. Psychological resilience in adulthood and later life: implications for health. Annu Rev Gerontol Geriatr. 2012;32:73–92.
Pfau ML, Russo SJ. Peripheral and central mechanisms of stress resilience. Neurobiol Stress. 2015;1:66–79.
Laird KT, Krause B, Funes C, Lavretsky H. Psychobiological factors of resilience and depression in late life. Transl Psychiatry. 2019;9:88.
Laird KT, Lavretsky H, St Cyr N, Siddarth P. Resilience predicts remission in antidepressant treatment of geriatric depression. Int J Geriatr Psychiatry. 2018;33:1596–603.
Struijs SY, de Jong PJ, Jeronimus BF, van der Does W, Riese H, Spinhoven P. Psychological risk factors and the course of depression and anxiety disorders: a review of 15 years NESDA research. J Affect Disord. 2021;295:1347–59.
Duckworth AL, Peterson C, Matthews MD, Kelly DR. Grit: perseverance and passion for long-term goals. J Pers Soc Psychol. 2007;92:1087–101.
Windsor TD, Curtis RG, Luszcz MA. Sense of purpose as a psychological resource for aging well. Dev Psychol. 2015;51:975–86.
Sowislo JF, Orth U. Does low self-esteem predict depression and anxiety? A meta-analysis of longitudinal studies. Psychol Bull. 2013;139:213–40.
Laird KT, Lavretsky H, Paholpak P, Vlasova RM, Roman M, St Cyr N, et al. Clinical correlates of resilience factors in geriatric depression. Int Psychogeriatr. 2019;31:193–202.
Cheng C, Lau HP, Chan MP. Coping flexibility and psychological adjustment to stressful life changes: a meta-analytic review. Psychol Bull. 2014;140:1582–607.
Cuijpers P, Karyotaki E, Pot AM, Park M, Reynolds CF 3rd. Managing depression in older age: psychological interventions. Maturitas. 2014;79:160–9.
Kiosses DN, Leon AC, Arean PA. Psychosocial interventions for late-life major depression: evidence-based treatments, predictors of treatment outcomes, and moderators of treatment effects. Psychiatr Clin North Am. 2011;34:377–401.
Shou H, Yang Z, Satterthwaite TD, Cook PA, Bruce SE, Shinohara RT, et al. Cognitive behavioral therapy increases amygdala connectivity with the cognitive control network in both MDD and PTSD. Neuroimage Clin. 2017;14:464–70.
Pinquart M, Duberstein PR, Lyness JM. Treatments for later-life depressive conditions: a meta-analytic comparison of pharmacotherapy and psychotherapy. Am J Psychiatry. 2006;163:1493–501.
Alexopoulos GS, Arean P. A model for streamlining psychotherapy in the RDoC era: the example of ‘Engage’. Mol Psychiatry. 2014;19:14–9.
Alexopoulos GS, Raue PJ, Banerjee S, Marino P, Renn BN, Solomonov N, et al. Comparing the streamlined psychotherapy “Engage” with problem-solving therapy in late-life major depression. A randomized clinical trial. Mol Psychiatry. 2021;26:5180–9.
Fung HH, Carstensen LL, Lang FR. Age-related patterns in social networks among European Americans and African Americans: implications for socioemotional selectivity across the life span. Int J Aging Hum Dev. 2001;52:185–206.
Schwarzbach M, Luppa M, Forstmeier S, Konig HH, Riedel-Heller SG. Social relations and depression in late life-a systematic review. Int J Geriatr Psychiatry. 2014;29:1–21.
Woods A, Solomonov N, Liles B, Guillod A, Kales HC, Sirey JA. Perceived social support and interpersonal functioning as predictors of treatment response among depressed older adults. Am J Geriatr Psychiatry. 2021;29:843–52.
Bosworth HB, McQuoid DR, George LK, Steffens DC. Time-to-remission from geriatric depression: psychosocial and clinical factors. Am J Geriatr Psychiatry. 2002;10:551–9.
King Johnson ML, Roche AI, Markon K, Denburg NL. Emotion regulation in older adulthood: roles of executive functioning and social relationships. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2023;30:336–53.
Donovan NJ, Wu Q, Rentz DM, Sperling RA, Marshall GA, Glymour MM. Loneliness, depression and cognitive function in older U.S. adults. Int J Geriatr Psychiatry. 2017;32:564–73.
Perissinotto CM, Stijacic Cenzer I, Covinsky KE. Loneliness in older persons: a predictor of functional decline and death. Arch Intern Med. 2012;172:1078–83.
Van Orden KA. Addressing loneliness in older adults during the COVID-19 pandemic: a commentary on “understanding psychological distress and protective factors among older adults during the COVID-19 pandemic”. Am J Geriatr Psychiatry. 2021;29:895–8.
Wilson RS, Krueger KR, Arnold SE, Schneider JA, Kelly JF, Barnes LL, et al. Loneliness and risk of Alzheimer disease. Arch Gen Psychiatry. 2007;64:234–40.
d’Oleire Uquillas F, Jacobs HIL, Biddle KD, Properzi M, Hanseeuw B, Schultz AP, et al. Regional tau pathology and loneliness in cognitively normal older adults. Transl Psychiatry. 2018;8:282.
Donovan NJ, Okereke OI, Vannini P, Amariglio RE, Rentz DM, Marshall GA, et al. Association of higher cortical amyloid burden with loneliness in cognitively normal older adults. JAMA Psychiatry. 2016;73:1230–7.
Chen JT, Wuthrich VM, Rapee RM, Draper B, Brodaty H, Cutler H, et al. Improving mental health and social participation outcomes in older adults with depression and anxiety: Study protocol for a randomised controlled trial. PLoS ONE. 2022;17:e0269981.
Tavares LR, Barbosa MR. Efficacy of group psychotherapy for geriatric depression: a systematic review. Arch Gerontol Geriatr. 2018;78:71–80.
Van Orden KA, Arean PA, Conwell Y. A pilot randomized trial of engage psychotherapy to increase social connection and reduce suicide risk in later life. Am J Geriatr Psychiatry. 2021;29:789–800.
Choi NG, Pepin R, Marti CN, Stevens CJ, Bruce ML. Improving social connectedness for homebound older adults: randomized controlled trial of tele-delivered behavioral activation versus tele-delivered friendly visits. Am J Geriatr Psychiatry. 2020;28:698–708.
Bruce ML, Pepin R, Marti CN, Stevens CJ, Choi NG. One year impact on social connectedness for homebound older adults: randomized controlled trial of tele-delivered behavioral activation versus tele-delivered friendly visits. Am J Geriatr Psychiatry. 2021;29:771–6.
Kahlon MK, Aksan N, Aubrey R, Clark N, Cowley-Morillo M, Jacobs EA, et al. Effect of layperson-delivered, empathy-focused program of telephone calls on loneliness, depression, and anxiety among adults during the COVID-19 pandemic: a randomized clinical trial. JAMA Psychiatry. 2021;78:616–22.
Szymkowicz SM, Ryan C, Elson DM, Kang H, Taylor WD. Cognitive phenotypes in late-life depression. Int Psychogeriatr. 2023;35:193–205.
Dotson VM. Can we promote cognitive resilience in late-life depression? Int Psychogeriatr. 2023;35:171–3.
Morimoto SS, Wexler BE, Alexopoulos GS. Neuroplasticity-based computerized cognitive remediation for geriatric depression. Int J Geriatr Psychiatry. 2012;27:1239–47.
Morimoto SS, Gunning FM, Wexler BE, Hu W, Ilieva I, Liu J, et al. Executive dysfunction predicts treatment response to neuroplasticity-based computerized cognitive remediation (nCCR-GD) in elderly patients with major depression. Am J Geriatr Psychiatry. 2016;24:816–20.
Gunning FM, Anguera JA, Victoria LW, Arean PA. A digital intervention targeting cognitive control network dysfunction in middle age and older adults with major depression. Transl Psychiatry. 2021;11:269.
Oberlin LE, Jaywant A, Wolff A, Gunning FM. Strategies to promote cognitive health in aging: recent evidence and innovations. Curr Psychiatry Rep. 2022;24:441–50.
Cao W, Cao X, Hou C, Li T, Cheng Y, Jiang L, et al. Effects of cognitive training on resting-state functional connectivity of default mode, salience, and central executive networks. Front Aging Neurosci. 2016;8:70.
Locke DEC, Khayoun R, Shandera-Ochsner AL, Cuc A, Eilertsen J, Caselli M, et al. Innovation inspired by COVID: a virtual treatment program for patients with mild cognitive impairment at Mayo Clinic. Mayo Clin Proc Innov Qual Outcomes. 2021;5:820–6.
Rebok GW, Ball K, Guey LT, Jones RN, Kim HY, King JW, et al. Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults. J Am Geriatr Soc. 2014;62:16–24.
Szymkowicz SM, Taylor WD, Woods AJ. Augmenting cognitive training with bifrontal tDCS decreases subclinical depressive symptoms in older adults: preliminary findings. Brain Stimul. 2022;15:1037–9.
Nevitt MC, Cummings SR, Kidd S, Black D. Risk factors for recurrent nonsyncopal falls. A prospective study. J Am Med Assoc. 1989;261:2663–8.
Seidler RD, Alberts JL, Stelmach GE. Changes in multi-joint performance with age. Mot Control. 2002;6:19–31.
Penninx BW, Ferrucci L, Leveille SG, Rantanen T, Pahor M, Guralnik JM. Lower extremity performance in nondisabled older persons as a predictor of subsequent hospitalization. J Gerontol A Biol Sci Med Sci. 2000;55:M691–7.
Abellan van Kan G, Rolland Y, Andrieu S, Bauer J, Beauchet O, Bonnefoy M, et al. Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) Task Force. J Nutr Health Aging. 2009;13:881–9.
White DK, Neogi T, Nevitt MC, Peloquin CE, Zhu Y, Boudreau RM, et al. Trajectories of gait speed predict mortality in well-functioning older adults: the Health, Aging and Body Composition study. J Gerontol A Biol Sci Med Sci. 2013;68:456–64.
Verghese J, Holtzer R, Lipton RB, Wang C. Quantitative gait markers and incident fall risk in older adults. J Gerontol A Biol Sci Med Sci. 2009;64:896–901.
Guralnik JM, Ferrucci L, Pieper CF, Leveille SG, Markides KS, Ostir GV, et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci. 2000;55:M221–31.
Montero-Odasso M, Schapira M, Soriano ER, Varela M, Kaplan R, Camera LA, et al. Gait velocity as a single predictor of adverse events in healthy seniors aged 75 years and older. J Gerontol A Biol Sci Med Sci. 2005;60:1304–9.
Zheng JJ, Lord SR, Close JC, Sachdev PS, Wen W, Brodaty H, et al. Brain white matter hyperintensities, executive dysfunction, instability, and falls in older people: a prospective cohort study. J Gerontol A Biol Sci Med Sci. 2012;67:1085–91.
Crockett RA, Hsu CL, Dao E, Tam R, Alkeridy W, Eng JJ, et al. Mind the gaps: functional networks disrupted by white matter hyperintensities are associated with greater falls risk. Neurobiol Aging. 2022;109:166–75.
Wegner M, Helmich I, Machado S, Nardi AE, Arias-Carrion O, Budde H. Effects of exercise on anxiety and depression disorders: review of meta-analyses and neurobiological mechanisms. CNS Neurol Disord Drug Targets. 2014;13:1002–14.
Klil-Drori S, Klil-Drori AJ, Pira S, Rej S. Exercise intervention for late-life depression: a meta-analysis. J Clin Psychiatry. 2020;81:19r12877.
Rhyner KT, Watts A. Exercise and depressive symptoms in older adults: a systematic meta-analytic review. J Aging Phys Act. 2016;24:234–46.
Firth J, Stubbs B, Vancampfort D, Schuch F, Lagopoulos J, Rosenbaum S, et al. Effect of aerobic exercise on hippocampal volume in humans: a systematic review and meta-analysis. Neuroimage 2018;166:230–8.
Kilpatrick LA, Siddarth P, Milillo MM, Krause-Sorio B, Ercoli L, Narr KL, et al. Impact of Tai Chi as an adjunct treatment on brain connectivity in geriatric depression. J Affect Disord. 2022;315:1–6.
Prehn K, Lesemann A, Krey G, Witte AV, Kobe T, Grittner U, et al. Using resting-state fMRI to assess the effect of aerobic exercise on functional connectivity of the DLPFC in older overweight adults. Brain Cogn. 2019;131:34–44.
Belvederi Murri M, Amore M, Menchetti M, Toni G, Neviani F, Cerri M, et al. Physical exercise for late-life major depression. Br J Psychiatry. 2015;207:235–42.
Erickson KI, Hillman C, Stillman CM, Ballard RM, Bloodgood B, Conroy DE, et al. Physical activity, cognition, and brain outcomes: a review of the 2018 physical activity guidelines. Med Sci Sports Exerc. 2019;51:1242–51.
Northey JM, Cherbuin N, Pumpa KL, Smee DJ, Rattray B. Exercise interventions for cognitive function in adults older than 50: a systematic review with meta-analysis. Br J Sports Med. 2018;52:154–60.
Sanders LMJ, Hortobagyi T, la Bastide-van Gemert S, van der Zee EA, van Heuvelen MJG. Dose-response relationship between exercise and cognitive function in older adults with and without cognitive impairment: a systematic review and meta-analysis. PLoS ONE. 2019;14:e0210036.
Hall AJ, Febrey S, Goodwin VA. Physical interventions for people with more advanced dementia—a scoping review. BMC Geriatr. 2021;21:675.
Laird KT, Paholpak P, Roman M, Rahi B, Lavretsky H. Mind-body therapies for late-life mental and cognitive health. Curr Psychiatry Rep. 2018;20:2.
Chou KL. Combined effect of vision and hearing impairment on depression in older adults: evidence from the English Longitudinal Study of Ageing. J Affect Disord. 2008;106:191–6.
Brewster KK, Ciarleglio A, Brown PJ, Chen C, Kim HO, Roose SP, et al. Age-related hearing loss and its association with depression in later life. Am J Geriatr Psychiatry. 2018;26:788–96.
Simning A, Fox ML, Barnett SL, Sorensen S, Conwell Y. Depressive and anxiety symptoms in older adults with auditory, vision, and dual sensory impairment. J Aging Health. 2019;31:1353–75.
Casten RJ, Rovner BW. Update on depression and age-related macular degeneration. Curr Opin Ophthalmol. 2013;24:239–43.
Horowitz A, Reinhardt JP, Kennedy GJ. Major and subthreshold depression among older adults seeking vision rehabilitation services. Am J Geriatr Psychiatry. 2005;13:180–7.
Rutherford BR, Brewster K, Golub JS, Kim AH, Roose SP. Sensation and psychiatry: linking age-related hearing loss to late-life depression and cognitive decline. Am J Psychiatry. 2018;175:215–24.
Heine C, Browning CJ. Mental health and dual sensory loss in older adults: a systematic review. Front Aging Neurosci. 2014;6:83.
Vink D, Aartsen MJ, Schoevers RA. Risk factors for anxiety and depression in the elderly: a review. J Affect Disord. 2008;106:29–44.
Chen DS, Betz J, Yaffe K, Ayonayon HN, Kritchevsky S, Martin KR, et al. Association of hearing impairment with declines in physical functioning and the risk of disability in older adults. J Gerontol A Biol Sci Med Sci. 2015;70:654–61.
Brewster KK, Hu MC, Zilcha-Mano S, Stein A, Brown PJ, Wall MM, et al. Age-related hearing loss, late-life depression, and risk for incident dementia in older adults. J Gerontol A Biol Sci Med Sci. 2021;76:827–34.
Horowitz A, Brennan M, Reinhardt JP, Macmillan T. The impact of assistive device use on disability and depression among older adults with age-related vision impairments. J Gerontol B Psychol Sci Soc Sci. 2006;61:S274–80.
Brody BL, Roch-Levecq AC, Kaplan RM, Moutier CY, Brown SI. Age-related macular degeneration: self-management and reduction of depressive symptoms in a randomized, controlled study. J Am Geriatr Soc. 2006;54:1557–62.
Rovner BW, Casten RJ, Hegel MT, Massof RW, Leiby BE, Ho AC, et al. Low vision depression prevention trial in age-related macular degeneration: a randomized clinical trial. Ophthalmology. 2014;121:2204–11.
Brewster K, Choi CJ, He X, Kim AH, Golub JS, Brown PJ, et al. Hearing rehabilitative treatment for older adults with comorbid hearing loss and depression: effects on depressive symptoms and executive function. Am J Geriatr Psychiatry. 2022;30:448–58.
Brewster KK, Pavlicova M, Stein A, Chen M, Chen C, Brown PJ, et al. A pilot randomized controlled trial of hearing aids to improve mood and cognition in older adults. Int J Geriatr Psychiatry. 2020;35:842–50.
Mulrow CD, Aguilar C, Endicott JE, Tuley MR, Velez R, Charlip WS, et al. Quality-of-life changes and hearing impairment. A randomized trial. Ann Intern Med. 1990;113:188–94.